NPC(SH:600713) Shang Hai Zheng Quan Bao·2025-11-19 18:59Group 1 - The core point of the announcement is the resolution of the second extraordinary general meeting of shareholders held by Nanjing Pharmaceutical Co., Ltd. on November 19, 2025, with no rejected proposals [2][4][6] - The meeting was convened by the board of directors and chaired by Chairman Zhou Jianjun, complying with relevant laws and regulations [2][3] - The attendance included 7 out of 8 directors, 2 out of 3 supervisors, and the company secretary, with some senior management present [3] Group 2 - Several proposals were reviewed and passed, including amendments to the company's articles of association, cancellation of the supervisory board, and changes to the company's name and registered capital [4][5] - The first three proposals were special resolutions, requiring more than two-thirds of the voting rights present at the meeting to pass [5] - The legal validity of the meeting and the voting process was confirmed by the witnessing lawyers from Beijing Jingtian Gongcheng Law Firm [6]